Prof. Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Korea Yuseong-Gu, Taejon-jikhalsi, Republic of Korea
Abstract:
Background: At present, there is no established biomarker for diagnosing non-infectious inflammatory central nervous system diseases. S100B, an astrocytic protein, is associated with inflammatory processes in the central nervous system.Hypothesis: We hypothesized that S100B would be elevated in dogs with MUO compared to healthy controls (HC) and idiopathic epilepsy (IE), suggesting its potential as a biomarker for MUO.Animals: Forty-one client-owned dogs. 14 dogs with MUO, 13 dogs with IE, and 14 healthy dogs.
Methods: A case-control study. S100B was estimated using a canine-specific enzyme-linked immunosorbent assay kit. Nonparametric and inferential statistics were used.
Results: Cerebrospinal fluid (CSF) S100B levels were significantly increased in MUO dogs compared to both HC (P = .000) and IE (P = .005). Serum S100B levels were also significantly higher in MUO dogs compared to HC (P = .000) and IE (P = .000). There is no significant difference in S100B levels between HC and IE in both CSF (P = .323) and serum (P = .155). A significantly strong correlation was found between S100B levels in CSF and serum (rs = .652, P = .000). In receiver operating characteristic (ROC) curve analysis for MUO versus control with CSF S100B, a cutoff value of 699.11 pg/mL showed 85.7% sensitivity, 84.2% specificity; at 835.82 pg/mL, sensitivity was 71.4%, specificity 100%. For serum S100B, a cutoff value of 782.39 pg/mL had 100% sensitivity, 84.2% specificity, and 977.06 pg/mL showed 85.7% sensitivity, 100% specificity.
Conclusions: Both CSF and serum S100B could be potential diagnostic biomarkers for MUO.
